Related Experiment Videos
Improved systemic ventricular function after carvedilol administration in a patient with congenitally corrected
JoAnn Lindenfeld1, Karin Keller, David N Campbell
1Division of Cardiology, University of Colorado Hospital and Children's Hospital, University of Colorado Health Sciences Center, Denver, Colorado, USA. joAnn.lindenfield@uchsc.edu
Insights
Congenitally corrected transposition of the great arteries (CCTGA) can cause heart problems. This study shows carvedilol improved heart function in an adult CCTGA patient.
Area of Science:
- Cardiology
- Congenital Heart Disease Research
Background:
- Congenitally corrected transposition of the great arteries (CCTGA) is a rare congenital heart defect.
- Systemic ventricular systolic dysfunction is a common complication, leading to reduced survival rates.
Observation:
- A 63-year-old male patient with CCTGA presented with symptoms related to systemic ventricular dysfunction.
- The patient was treated with carvedilol, a beta-blocker with alpha-blocking activity.
Findings:
- Carvedilol treatment resulted in a significant improvement in the systemic ventricular function.
- This suggests a potential therapeutic benefit of carvedilol in managing CCTGA-associated cardiac dysfunction.
Implications:
- Carvedilol may be a viable treatment option for improving outcomes in adult patients with CCTGA.
- Further research is warranted to explore the long-term efficacy and safety of carvedilol in this patient population.
Abstract:
Congenitally corrected transposition of the great arteries (CCTGA) is associated with shortened survival due, at least in part, to progressive systolic dysfunction of the systemic ventricle. We report a substantial improvement in systemic ventricular function with carvedilol in a 63-year-old man with CCTGA.